Compare Oxford Lane Capital Corp (OXLC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs BIO-TECHNE Corp — how do they compare? Oxford Lane Capital Corp trades at $8.62 (market cap $829.34M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 13.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.37%). Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 49 Days and BIO-TECHNE Corp for 63 Days on average.
| OXLC | TECH | |
|---|---|---|
Market Cap | $829.34M | $11.37B |
Volume | 1,709,917 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $16.74 | $72.61 |
52-Week Low | $8.15 | $43.31 |
Typical Hold Time | 49 Days | 63 Days |
Enterprise Value | $1.22B | $11.40B |
Dividend Yield | 28.37% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook and negative profitability metrics. Recent earnings misses and a sharp decline in net income for 2026 highlight fundamental challenges, though the stock pays consistent dividends. Analyst sentiment is mixed, with a 50% buy rating but cautious media coverage on sustainability.
The outlook remains risky due to volatile earnings, high payout ratios, and NAV erosion. Potential exists for value investors attracted by the P/B discount and high yield, but significant headwinds in CLO market exposure and operational cash flow deficits warrant caution for near-term performance.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
